ライフサイエンスコーパス: iron dextran

1 s, was increased three-fold by high doses of iron dextran.

2 one to 15 weekly subcutaneous injections of iron dextran.

3 ability shift were revealed below 500 mug/mL iron dextran.

4 t mice that included daily administration of iron dextran.

5 iron carbonyl in the diet, or injected with iron dextran.

6 ongolian gerbil given repeated injections of iron dextran.

7 phrine administrations, both associated with iron dextran.

8 e absence of administered iron, but not when iron dextran (300-500 mg Fe/kg) was administered.

9 ly subcutaneous injections of either 1 mL of iron dextran (5 mg/mL) or 0.9% NaCl for a total of five

10 red within a 12-week period was highest with iron dextran (82 per 100,000 persons, 95% CI, 70.5- 93.1

11 irst exposure was 68 per 100,000 persons for iron dextran (95% CI, 57.8-78.7 per 100,000) and 24 per

12 We examined the effects of chronic iron dextran administration (15 mg over 6 weeks) on thro

13 Neither an Hfe-null mutation nor iron-dextran administration alone or in combination with

14 omozygosity for an Hfe-null mutation but not iron-dextran administration was porphyrinogenic in anima

15 n but not to the extent seen with parenteral iron-dextran administration.

16 High-dose iron supplementation with iron dextran after the onset of sepsis significantly inc

17 ron, the risk of anaphylaxis was highest for iron dextran and lowest for iron sucrose.

18 /-) zebrafish were rescued by injection with iron dextran and studied in comparison with injected and

19 IDA infants were then administered iron dextran and vitamin B via intramuscular injections

20 When URO-D(+/-) mice were injected with iron-dextran and given drinking water containing delta-a

21 l mutation and polychlorinated biphenyls and iron-dextran and polychlorinated biphenyls.

22 with 1.2 g elemental iron/kg body weight as iron dextran) and pair-fed control groups.

23 erated an iron-overloaded mouse by injecting iron dextran at 2 doses into C57/BL6 mice for 2 months.

24 Iron, administered as an iron dextran complex or as a 1:1 chelate with nitrilotri

25 r complexes were introduced, e.g., InFed(R) (iron-dextran complex injection) in 1974 and Abraxane(R)

26 KIM5-infected mice treated daily with 4 mg iron dextran died in 3 days with severe pneumonia.

27 against KIM5 infections in mice administered iron dextran doses leading to light or severe pneumonia,

28 MDA was considerably increased even at low iron dextran doses, but without any increase in URO accu

29 Mice were first treated with iron dextran for 4 weeks to induce iron-overload cardiom

30 Administrations of IV iron dextran, gluconate, sucrose, or ferumoxytol as repo

31 f HIF-2alpha or parenteral administration of iron-dextran in HIF-2alpha knockout mothers ameliorated

32 ethanol for 6 to 7 months, administration of iron dextran increased hepatic URO accumulation and decr

33 ) deformability in vitro was assessed during iron dextran (INFeD) loading and/or ethanol co-administr

34 ls < 600 ng/mL were treated with intravenous iron dextran (INFeD; Schein Pharmaceutical Inc., Florham

35 uptake than wild-type littermates following iron dextran injection.

36 pplemented either directly in the diet or by iron dextran injection.

37 rmalized after rapid correction of IDA using iron dextran injections.

38 Injection of iron dextran into WT or mutant zebrafish embryos, howeve

39 nes the effects of a maintenance intravenous iron dextran (ivID) protocol that increased TSAT in ESRD

40 Twelve gerbils underwent iron dextran loading (200 mg . kg(-1) . wk(-1)) from 2 t

41 ed significant cell stiffening at 500 mug/mL iron dextran loading concentration (p < 0.05, Tukey test

42 dequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit

43 increased systemic iron availability (e.g., iron dextran or phenylhydrazine) on the induction, kinet

44 erloaded mice, including models of acquired (iron-dextran or stored red blood cells) and primary (Hfe

45 ous iron repletion (1 g low-molecular-weight iron dextran) or placebo.

46 nted when prescribing >10 vials (1000 mg) of iron dextran over a period of 6 mo.

47 iron; (2). oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextra

48 high-iron diet or by parenteral injection of iron dextran; rescue can also be achieved by providing a

49 Rapid correction of IDA with iron dextran resulted in extensive metabolic changes acr

50 n sucrose, 3.8% (n = 345, 95% CI: 3.4%-4.2%) iron dextran (test and full doses or test dose alone), 1

51 en they were injected intraperitoneally with iron dextran, though not with iron sulfate.

52 iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI).

53 , comprising 22 309 iron sucrose doses, 9067 iron dextran total doses (1771 preceded by test dose, 56

54 ains containing pGTR902 were inoculated into iron dextran-treated and untreated mice.

55 lesions in subcutaneously (s.c.) inoculated iron dextran-treated mice in terms of numbers of recover

56 results demonstrate that s.c. inoculation of iron dextran-treated mice is a useful model for studying

57 V. vulnificus inoculated into iron dextran-treated mice replicated extremely rapidly o

58 Studies with iron dextran-treated mice showed that vaccination with t

59 Infection of non-iron dextran-treated mice with clinical strains demonstr

60 In non-iron dextran-treated mice, strains required 10(5)-fold-h

61 ls of virulence in subcutaneously inoculated iron dextran-treated mice.

62 es adherence to HEp-2 cells and virulence in iron dextran-treated mice.

63 n period were not significantly different in iron dextran-treated mice; however, the rate of death of

64 r severe pneumonia, supporting the use of an iron dextran-treated model of pneumonic plague.

65 ly attenuated in a subcutaneously inoculated iron dextran-treated mouse model of V. vulnificus diseas

66 for virulence in a subcutaneously inoculated iron dextran-treated mouse model.

67 d for virulence in subcutaneously inoculated iron-dextran-treated mice.

68 erapeutic agents against V. vulnificus in an iron-dextran-treated mouse model of V. vulnificus infect

69 o cause an identical disease process as with iron dextran treatment.

70 ins demonstrated that the greatest effect of iron dextran-treatment was increased growth rate, while

71 sucrose, the adjusted OR of anaphylaxis for iron dextran was 3.6 (95% CI, 2.4-5.4); for iron glucona

72 Pneumonia was less severe if 4 mg iron dextran was administered only once before infection

73 Iron dextran was required in the bacterial inoculum to e